The first-line pharmacological treatment for prolactinoma includes dopamine agonists (DAs), such as bromocriptine or cabergoline (3), which aim to suppress excessive PRL secretion and reduce tumor size using the minimum effective dose. Here, PRL is linked to neoplasm.